Intravenous Immunoglobulin (IVIg) Market Analysis
The Global Intravenous Immunoglobulin (IVIg) Market is growing at a CAGR of 5.9% during the forecast period. It is expected to reach USD 8,337.2 million by 2023. Intravenous immunoglobulin (IVIg) is a treatment for patients with severe antibody deficiencies. They are manufactured from human plasma and contain immunoglobulin G (IgG) pooled from nearly 1500 donors. The global intravenous immunoglobulin (IVIg) market report by Market Research Future (MRFR) comprises drivers, challenges, opportunities, and trends for the period of 2016 to 2023 (forecast period). The COVID-19 outbreak and the measures taken by companies to tackle production and supply chain problems are discussed in the report.
Request Free Sample Copy of the report “Intravenous Immunoglobulin (IVIg) Market Research Report Forecast To 2023” at: https://www.marketresearchfuture.com/sample_request/3137
The huge prevalence of immunodeficiency diseases is the primary driver of the intravenous immunoglobulin (IVIg) market. According to the WHO, there are close to 50 primary immunodeficiency diseases including X-lined hypo-gamma-globulinemia, specific antibody-deficiency, and others. IVIg has shown success in suppressing the propagation of antigen-specific T cells without inducing apoptosis. Investments in healthcare, the growing geriatric population, and rising cases of bleeding disorders are other drivers of the intravenous immunoglobulin (IVIg) market. Rise of subcutaneous immunoglobulin in replacement therapy can provide ample scope for the market.
The propagation of the COVID-19 virus has led to the use of IVIg therapies for its treatment. This is evident by the recent surge in plasma donors. IVIg can prevent the attachment of SARS-CoV2 protein to ACE2 receptor and restrict the entry of the virus into the cell. Studies supporting the seroconversion within patients after being treated with plasma therapy are expected to make huge inroads as a primary step of treatment for the virus.
Intravenous Immunoglobulin (IVIg) Market Segmentation
The global intravenous immunoglobulin (IVIg) market has been segmented on the basis of type into IgA (sub segments- IgA1 and IgA2), IgG, IgD, and IgE.
On the basis of application, the global intravenous immunoglobulin (IVIg) market is segmented into hypogammaglobulinemia (sub segments- AGM1, AGM2, AGM3, AGM4, AGM5, AGM6), myasthenia gravis (Sub segments- generalized myasthenia gravis, ocular myasthenia gravis, congenital myasthenia gravis, transient neonatal myasthenia gravis), multifocal motor neuropathy, immunodeficiency diseases (sub segments- X-linked agammaglobulinemia (XLA), common variable immunodeficiency (CVID), severe combined immunodeficiency), CIDP (Progressive, Recurrent, Monophasic), primary humoral immunodeficiency (Subsegments- B cell (antibody) deficiencies, T cell deficiencies, combination B and T cell deficiencies, defective phagocytes, complement deficiencies, Unknown (idiopathic)), Guillain-Barré syndrome (sub segments – acute motor axonal neuropathy (AMAN), Miller Fisher syndrome (MFS), acute inflammatory demyelinating polyradiculoneuropathy (AIDP), and acute motor-sensory axonal neuropathy (AMSAN)), Kawasaki disease, ITP (Sub segments – acute and chronic), and others.
Intravenous Immunoglobulin (IVIg) Market Regional Analysis
Considering the global scenario of the market, North America is believed to be the largest market IVIg. This can be attributed to the large population, supportive healthcare framework, and high awareness levels pertaining to plasma protein. Moreover the European market, especially Western Europe is growing, and the second largest market for global IVIg.
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/intravenous-immunoglobulin-market-3137
On the other hand, APAC is expected to grow at significant rate in the global IVIg market during the forecasted period. Adoption of immunoglobulin based therapies for treatment of PIDs and its awareness among the patient pool can drive the regional market growth. The Middle East and Africa (MEA) is likely to have a limited but steady growth in the intravenous immunoglobulin (IVIg) market particularly in North Africa.
Intravenous Immunoglobulin (IVIg) Market Competitive Intelligence
China Biologic Products, Inc., ABEONA THERAPEUTICS, Shire, Kedrion S.p.A, Octapharma, BDI Pharma, Grifols Inc., Baxter, CSL Behring, and Biotest AG are key players of the global intravenous immunoglobulin market.
Browse Related Research Reports at:
The global digital health market size is touted to reach USD 328,887.8 million by 2025
The Global Digital Diabetes Management Market size is anticipated to exhibit 23.7% CAGR during the forecast period.
NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/intravenous-immunoglobulin-market-3137